Drug intelligence / Profile preview

azd9742

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous

Overview

AZD9742 is an investigational antibacterial small molecule developed by AstraZeneca. It acts as an inhibitor of bacterial DNA gyrase and topoisomerase IV, targeting essential enzymes involved in bacterial DNA replication and topology. The drug was designed to address infections caused by resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Its mechanism of action is distinct from fluoroquinolones, offering a novel approach to overcoming resistance. AZD9742 was administered intravenously in clinical studies and reached Phase 1 trials in healthy volunteers but did not progress further in development.

Other names: AZD-9742AZD9742AZD 9742

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on azd9742.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azd9742.

Explore the full profile